Anzeige
Meldung des Tages: Der neue Superzyklus: Warum Kupfer jetzt strategisch unverzichtbar wird und wer profitieren könnte
Werbung
Attraktive Knock-Outs auf Viatris Inc
Typ Hebel Bid / Ask WKN
Call
1,9 5,61 € / 5,63 €
SU0UF7
Typ Hebel Bid / Ask WKN
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Viatris Inc

Viatris Aktie News

Aktie
WKN:  A2QAME ISIN:  US92556V1061 US-Symbol:  VTRS Branche:  Pharmazeutika Land:  USA
12,66 $
-0,2 $
-1,56%
10,795 € 20.01.26
Depot/Watchlist
Marktkapitalisierung *
12,24 Mrd. €
Streubesitz
12,81%
KGV
-23,49
Dividende
0,12 $
Dividendenrendite
0,94%
neu: Nachhaltigkeits-Score
42 %
Index-Zuordnung
S&P 500

Viatris News

20.01.26 - PR Newswire
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure PR Newswire
08.01.26 - PR Newswire
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer PR Newswire
18.12.25 - PR Newswire
Viatris Provides Pipeline Update on Four Regulatory Milestones
Viatris Provides Pipeline Update on Four Regulatory Milestones PR Newswire
17.12.25 - PR Newswire
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
06.12.25 - PR Newswire
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited PR Newswire
24.11.25 - PR Newswire
Viatris to Participate in Upcoming Investor Conferences
Viatris to Participate in Upcoming Investor Conferences PR Newswire
19.11.25 - PR Newswire
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und Medicines for Europe vorgestellt wurden
Europäische Studie zeigt sinkende Preise, steigende Kosten und Engpässe - Ergebnisse einer unabhängigen Studie, die während der World AMR Awareness Week von Viatris und ...
19.11.25 - PR Newswire
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for Europe
European study shows falling prices, rising costs and shortages - findings from independent study presented during World AMR Awareness Week by Viatris and Medicines for ...
13.11.25 - PR Newswire
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025 PR Newswire
06.11.25 - PR Newswire
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance
Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance PR Newswire
04.11.25 - PR Newswire
Viatris Announces Quarterly Dividend
Viatris Announces Quarterly Dividend PR Newswire
15.10.25 - PR Newswire
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-​Pacific Region PR ...
13.10.25 - PR Newswire
Viatris to Participate in Upcoming Investor Conferences
Viatris to Participate in Upcoming Investor Conferences PR Newswire
08.10.25 - PR Newswire
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row PR Newswire
01.10.25 - PR Newswire
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025
Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 PR Newswire
30.08.25 - wallstreetONLINE Redaktion
Börsen-Nieten im Fokus: Diese 10 S&P-500-Aktien haben ein Jahrzehnt lang nur enttäuscht – bis jetzt!
Langfristige Verluste sind im S&P 500 eine Seltenheit – doch zehn Aktien haben in den vergangenen zehn Jahren klar enttäuscht. Welche dieser Nachzügler jetzt mit starken ...
19.08.25 - PR Newswire
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer PR Newswire
11.08.25 - PR Newswire
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. PR Newswire
07.08.25 - PR Newswire
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance
Viatris Reports Second Quarter 2025 Results and Reiterates 2025 Financial Guidance PR Newswire
05.08.25 - PR Newswire
Viatris Announces Quarterly Dividend
Viatris Announces Quarterly Dividend PR Newswire

Newssuche

Videos

newspaper
20.01.26 +2,43%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »